When to screen and not to screen
Open accessAbstract
Colorectal cancer (CRC) is the third most common cause of cancer-related deaths with treatment of advanced and metastatic CRC (mCRC) remaining palliative at best. (1) The epidermal growth factor receptor (EGFR) has been identified as a therapeutic target for a multitude of malignancies, including mCRC. Ligand-binding to EGFR results in the subsequent activation of multiple signal transduction pathways including the PI3K/AKT and RAS/RAF/MAPK pathways, which are vital for cell growth and survival. (2) Constitutive activation of these signaling pathways leads to deregulated cellular proliferation, malignant progression, and invasion. (3.)
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The S492R mutation does not confer resistance to panitumumab.
“Fortunately, the S492R mutation does not confer resistance to panitumumab [33,35,36,37].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Esposito, C., Rachiglio, A. M., La Porta, M. L., Sacco, A., Roma, C., Iannaccone, A., Tatangelo, F., Forgione, L., Pasquale, R., Barbaro, A., et al. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.26340 · Cited by 53 · see citing works
Osumi, H., Matsusaka, S., Shinozaki, E., Suenaga, M., Mingyon, M., Saiura, A., Ueno, M., Mizunuma, N., & Yamaguchi, T. (2013) · BMC Research Notes · doi:10.1186/1756-0500-6-508 · Cited by 9 · see citing works
Flagged first, then by citations
Research works printed but not linked: 6
- [1]Rizzo S, Bronte G, Fanale D, Corsini L, Silvestris N, Santini D, Gulotta G, Bazan V, Gebbia N, Fulfaro F, et al. Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?. Cancer Treat Rev 2010; 36: Suppl 3 S56 - 61; http://dx.doi.org/ 10.1016/S0305-7372(10)70021-9; PMID: 21129611 21129611 · DOI
- [2]Tomas A, Futter CE, Eden ER. EGF receptor trafficking: consequences for signaling and cancer. Trends Cell Biol 2014; 24: 26 - 34; http://dx.doi.org/ 10.1016/j.tcb.2013.11.002; PMID: 24295852 24295852 PMC3884125 · DOI
- [3]Thiel A, Ristimäki A. Toward a Molecular Classification of Colorectal Cancer: The Role of BRAF. Front Oncol 2013; 3: 281; http://dx.doi.org/ 10.3389/fonc.2013.00281; PMID: 24298448 24298448 PMC3828559 · DOI
- [4]Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337 - 45; http://dx.doi.org/ 10.1056/NEJMoa033025; PMID: 15269313 15269313 · DOI · Paper page
- [6]Markman B, Javier Ramos F, Capdevila J, Tabernero J. EGFR and KRAS in colorectal cancer. Adv Clin Chem 2010; 51: 71 - 119; http://dx.doi.org/ 10.1016/S0065-2423(10)51004-7; PMID: 20857619 20857619 · DOI
- [7]Tougeron D, Cortes U, Ferru A, Villalva C, Silvain C, Tourani JM, Levillain P, Karayan-Tapon L. Epidermal growth factor receptor (EGFR) and KRAS mutations during chemotherapy plus anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer. Cancer Chemother Pharmacol 2013; 72: 397 - 403; http://dx.doi.org/ 10.1007/s00280-013-2211-0; PMID: 23765179 23765179 · DOI
Cited by
Sorted by citations
Henrykowska, G., Bartusik-Aebisher, D., Dynarowicz, K., Ramesh, T. S., Smolak, B., & Aebisher, D. (2026) · Pharmaceuticals · doi:10.3390/ph19071041 · Cited by 1 · see citing works
“Fortunately, the S492R mutation does not confer resistance to panitumumab [33,35–37].”
- Authors
- Cruickshanks, N.
- Affiliations
- Virginia Commonwealth University (US)
- Corresponding author
- Cruickshanks, Nichola
- Venue
- Cancer Biology & Therapy
- Publisher
- Informa UK Limited
- Published
- 2014-01-14
- Volume
- 15
- Issue
- 2
- Pages
- 147-148
- ISSN
- 1538-4047 (ISSN-L)
- 1555-8576
- PMC
- PMC5115864
- OpenAlex
- W2078787351
- Cited by
- 1
- References
- 2
- Citations by year
- 2018: 1
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Cancer Biology & Therapy (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Keywords
- colorectal cancer, metastatic colorectal cancer, EGFR, epidermal growth factor receptor, PI3K/Akt signaling, Ras/Raf/MAPK signaling, signal transduction, therapeutic target, cancer screening
- MeSH terms
- Antibodies, Monoclonal, Antineoplastic Agents, Female, Humans, Male, Proto-Oncogene Proteins, Colorectal Neoplasms, ras Proteins, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
